Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neurocrine (NBIX), SAGE Therapeutics (SAGE) and Biogen (BIIB)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIXResearch Report), SAGE Therapeutics (SAGEResearch Report) and Biogen (BIIBResearch Report).

Neurocrine (NBIX)

In a report issued on October 14, Ami Fadia from Needham maintained a Hold rating on Neurocrine. The company’s shares closed last Monday at $88.47.

According to TipRanks.com, Fadia is a 1-star analyst with an average return of -0.8% and a 42.5% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $119.87 average price target, implying a 39.5% upside from current levels. In a report issued on November 22, Leerink Partners also initiated coverage with a Hold rating on the stock with a $100.00 price target.

See the top stocks recommended by analysts >>

SAGE Therapeutics (SAGE)

In a report issued on November 2, Tim Lugo from William Blair maintained a Hold rating on SAGE Therapeutics. The company’s shares closed last Monday at $43.59, close to its 52-week low of $36.13.

According to TipRanks.com, Lugo is a 4-star analyst with an average return of 13.4% and a 45.9% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.

Currently, the analyst consensus on SAGE Therapeutics is a Moderate Buy with an average price target of $63.92, implying a 49.0% upside from current levels. In a report issued on October 19, Morgan Stanley also initiated coverage with a Hold rating on the stock with a $66.00 price target.

Biogen (BIIB)

In a report issued on December 1, Myles Minter from William Blair maintained a Buy rating on Biogen. The company’s shares closed last Monday at $244.14, close to its 52-week low of $221.72.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.9% and a 54.9% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Neurocrine, and Alector.

Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $333.88, which is a 39.0% upside from current levels. In a report issued on November 18, BMO Capital also initiated coverage with a Buy rating on the stock with a $315.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NBIX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos